89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
89bio (Nasdaq: ETNB) has appointed Dr. Teresa Perney as Chief Regulatory and Quality Officer, effective immediately. Dr. Perney brings over 20 years of experience in the biotech and pharmaceutical industry, with expertise in regulatory affairs, product development, and quality assurance. This appointment comes as 89bio advances pegozafermin through multiple global Phase 3 studies for liver and cardiometabolic diseases.
CEO Rohan Palekar emphasized that Dr. Perney's expertise will be important in shaping the company's global regulatory strategy and potentially accelerating the delivery of pegozafermin to patients worldwide. Dr. Perney expressed excitement about joining 89bio at this pivotal moment and leveraging her experience to address unmet needs in liver and cardiometabolic diseases.
89bio (Nasdaq: ETNB) ha nominato Dr. Teresa Perney come Chief Regulatory and Quality Officer, con effetto immediato. La Dr. Perney porta oltre 20 anni di esperienza nell'industria biotecnologica e farmaceutica, con competenze in affari regolatori, sviluppo del prodotto e assicurazione della qualità. Questa nomina arriva mentre 89bio sta avanzando pegozafermin attraverso diversi studi globali di Fase 3 per le malattie epatiche e cardiometaboliche.
Il CEO Rohan Palekar ha sottolineato che l'esperienza della Dr. Perney sarà importante nella definizione della strategia globale dell'azienda in materia di regolamentazione e potenzialmente nell'accelerare la consegna di pegozafermin ai pazienti in tutto il mondo. La Dr. Perney ha espresso entusiasmo per unirsi a 89bio in questo momento cruciale e per utilizzare la sua esperienza per affrontare i bisogni insoddisfatti nelle malattie epatiche e cardiometaboliche.
89bio (Nasdaq: ETNB) ha nombrado a la Dr. Teresa Perney como Directora de Regulación y Calidad, con efecto inmediato. La Dra. Perney aporta más de 20 años de experiencia en la industria biotecnológica y farmacéutica, con experiencia en asuntos regulatorios, desarrollo de productos y aseguramiento de la calidad. Este nombramiento llega mientras 89bio avanza pegozafermin a través de múltiples estudios globales de Fase 3 para enfermedades del hígado y cardiometabólicas.
El CEO Rohan Palekar enfatizó que la experiencia de la Dra. Perney será importante para dar forma a la estrategia regulatoria global de la empresa y potencialmente acelerar la entrega de pegozafermin a pacientes en todo el mundo. La Dra. Perney expresó su entusiasmo por unirse a 89bio en este momento crucial y aprovechar su experiencia para abordar las necesidades no satisfechas en enfermedades hepatobiliares y cardiometabólicas.
89bio (Nasdaq: ETNB)는 Dr. Teresa Perney를 규제 및 품질 책임자로 즉각 임명했습니다. 페르니 박사는 생명공학 및 제약 산업에서 20년 이상의 경험을 갖고 있으며 규제 업무, 제품 개발 및 품질 보증에 대한 전문성이 있습니다. 이 임명은 89bio가 간 및 심대사 질환을 위한 다수의 글로벌 3상 연구를 진행하는 동안 이루어졌습니다.
CEO 로한 팔레카르는 페르니 박사의 전문성이 회사의 글로벌 규제 전략을 형성하는 데 중요하며, 전 세계의 환자에게 pegozafermin을 제공하는 속도를 높이는 데 기여할 것이라고 강조했습니다. 페르니 박사는 89bio에 합류하게 되어 기쁘며, 간 및 심대사 질환에서 해결되지 않은 요구를 해결하는 데 자신의 경험을 활용하고 싶다고 전했습니다.
89bio (Nasdaq: ETNB) a nommé Dr. Teresa Perney au poste de Directrice des Régulations et de la Qualité, avec effet immédiat. Dr. Perney apporte plus de 20 ans d'expérience dans l'industrie biotechnologique et pharmaceutique, avec une expertise en matière de réglementation, de développement de produits et d'assurance qualité. Cette nomination intervient alors qu'89bio fait progresser pegozafermin à travers plusieurs études mondiales de Phase 3 pour les maladies du foie et cardiométaboliques.
Le PDG Rohan Palekar a souligné que l'expertise de Dr. Perney sera essentielle pour façonner la stratégie réglementaire mondiale de l'entreprise et pourrait potentiellement accélérer l'acheminement de pegozafermin aux patients dans le monde entier. Dr. Perney a exprimé son enthousiasme à rejoindre 89bio à ce moment clé et à tirer parti de son expérience pour répondre aux besoins non satisfaits dans les maladies du foie et cardiométaboliques.
89bio (Nasdaq: ETNB) hat Dr. Teresa Perney sofort zur Chief Regulatory and Quality Officer ernannt. Dr. Perney bringt über 20 Jahre Erfahrung in der Biotech- und Pharmaindustrie mit, mit Fachkenntnissen in den Bereichen Regulierungsangelegenheiten, Produktentwicklung und Qualitätssicherung. Diese Ernennung erfolgt, während 89bio pegozafermin durch mehrere globale Phase-3-Studien für Leber- und kardiometabolische Krankheiten voranbringt.
CEO Rohan Palekar betonte, dass Dr. Perneys Fachkenntnisse wichtig sein werden, um die globale Regulierungsstrategie des Unternehmens zu gestalten und möglicherweise die Bereitstellung von pegozafermin für Patienten weltweit zu beschleunigen. Dr. Perney äußerte ihre Begeisterung, zu 89bio in diesem entscheidenden Moment zu stoßen und ihre Erfahrung zu nutzen, um unerfüllte Bedürfnisse bei Leber- und kardiometabolischen Erkrankungen zu adressieren.
- Appointment of experienced Chief Regulatory and Quality Officer strengthens leadership team
- Dr. Perney's expertise aligns with 89bio's focus on advancing pegozafermin through Phase 3 studies
- Potential to accelerate regulatory processes and drug delivery to patients
- None.
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company.
"We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio,” said Rohan Palekar, CEO of 89bio. “As we advance pegozafermin through multiple global Phase 3 studies, Dr. Perney's extensive expertise in regulatory affairs, product development, and quality assurance will be instrumental in shaping our global regulatory strategy. Her addition to our team significantly strengthens our ability to execute our strategic objectives and potentially accelerate the delivery of pegozafermin to patients in need worldwide."
Dr. Perney added, "I'm excited to join 89bio at this pivotal moment in the company's journey. The Phase 3 clinical development of pegozafermin represents a significant opportunity to potentially address critical unmet needs for patients with liver and cardiometabolic diseases. I'm eager to leverage my experience to navigate the regulatory landscape and help bring this innovative therapy to patients worldwide."
Dr. Perney brings over 20 years of relevant experience in the biotech and pharmaceutical industry. Most recently, she was Chief Regulatory and Quality Officer at EQRx prior to its acquisition by Revolution Medicines. Prior to that position, Dr. Perney served as Senior Vice President of Regulatory and Quality at Myovant Sciences, Vice President of Global Development for Oncology at Pfizer, Inc., and Vice President of Regulatory Affairs at Medivation. She also held Regulatory & Product Development positions at Hoffman LaRoche/Genentech and the Schering Plough Research Institute. Dr. Perney received her B.A. from Northwestern University and her Ph.D. in Neurobiology from the University of Chicago.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
Who is the new Chief Regulatory and Quality Officer at 89bio (ETNB)?
What is the main drug candidate 89bio (ETNB) is developing?
What is Dr. Teresa Perney's background before joining 89bio (ETNB)?
How might Dr. Perney's appointment impact 89bio's (ETNB) drug development process?
